These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21779641)

  • 1. Regulatory Impact Analysis: a new tool for better regulation at ANVISA.
    Alves FN; Peci A
    Rev Saude Publica; 2011 Aug; 45(4):802-5. PubMed ID: 21779641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Institutional change and political decision-making in the creation of the Brazilian National Health Surveillance Agency.
    Piovesan MF; Labra ME
    Cad Saude Publica; 2007 Jun; 23(6):1373-82. PubMed ID: 17546328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The National Health Surveillance Agency, ANVISA, and clinical research in Brazil].
    Nishioka Sde A; Sá PF
    Rev Assoc Med Bras (1992); 2006; 52(1):60-2. PubMed ID: 16622542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013-2016.
    Patel P; Cerqueira DM; Santos GML; de Lima Soares R; Sousa VD; Liberti L; McAuslane N
    Ther Innov Regul Sci; 2020 Nov; 54(6):1428-1435. PubMed ID: 32519282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sanitary regulation as part of health policy in Brazil: gaps and challenges].
    Maia C; Guilhem D
    Rev Panam Salud Publica; 2016 May; 39(5):226-231. PubMed ID: 27706402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
    Geyer ARC; Sousa VD; Silveira D
    PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.
    Barron AJ; Klinger C; Shah SM; Wright JS
    Health Policy; 2015 Feb; 119(2):137-46. PubMed ID: 25458970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the administrative regulation on occupational health and trend in China.
    Zhou Z
    J Occup Health; 2018 Mar; 60(2):126-131. PubMed ID: 29311440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory beneficiaries and informal agency policymaking.
    Mendelson NA
    Cornell Law Rev; 2007 Mar; 92(3):397-452. PubMed ID: 17410678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Air accident investigation among regulatory agencies.
    Fajer M; Fischer FM
    Work; 2012; 41 Suppl 1():175-7. PubMed ID: 22316718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality management as knowledge sharing: experiences of the Napa County Health and Human Services Agency.
    Harrison L
    J Evid Based Soc Work; 2012; 9(1-2):121-32. PubMed ID: 22409617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution and key elements of the Brazilian pharmacovigilance system: a scoping review beginning with the creation of the Brazilian Health Regulatory Agency.
    Mota DM; Vigo Á; Kuchenbecker RS
    Cad Saude Publica; 2018 Oct; 34(10):e00000218. PubMed ID: 30328994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data Integrity-A Study of Current Regulatory Thinking and Action.
    Shafiei N; De Montardy R; Rivera-Martinez E
    PDA J Pharm Sci Technol; 2015; 69(6):762-70. PubMed ID: 26659106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [40th anniversary of the 736th Main Center of State Sanitary and Epidemiological Surveillance of the Russian Defense Ministry].
    Soloveĭ ÈP; Berskiĭ OV; Ian'shin LA
    Voen Med Zh; 2012 Nov; 333(11):86-90. PubMed ID: 23301297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Protagonism of the Brazilian Health Regulatory System in the Evolution of Patient Safety in the Country: History, Dilemmas, and Current Challenges.
    Santana HT; Costa MMM; Nogueira MDSP; Dos Santos ACRB; Carvalho AA; Morelo LT; Ribeiro CFM; de Sousa FC; de Moura HLCA; Barros LS; de Oliveira LSC; Gonçalves MRS
    J Patient Saf; 2020 Dec; 16(4):e260-e266. PubMed ID: 32084092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory review: How do agencies ensure the quality of decision making?
    Liberti L; McAuslane N; Patel P; Breckenridge A; Eichler HG; Peterson R
    Clin Pharmacol Ther; 2013 Sep; 94(3):305-8. PubMed ID: 23963218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unquantified Benefits and the Problem of Regulation Under Uncertainty.
    Masur JS; Posner EA
    Cornell Law Rev; 2016 Nov; 102(1):87-137. PubMed ID: 27959485
    [No Abstract]   [Full Text] [Related]  

  • 19. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The U.S. NRC and the ADR process learning experiences.
    Pérez-Monté JE
    Health Phys; 2011 Nov; 101 Suppl 3():S160-3. PubMed ID: 21968823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.